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The atrial natriuretic peptide (ANP) has been shown to
modulate hypertrophy of the heart via the cardiac NP
receptor guanylyl cyclase-A (GC-A) [1]. Also, analysis of
transgenic mice with a cardiomyocyte (cM) specific over-
expression of GC-A and the chronic inhibition of the
cGMP-degrading phosphodiesterase-5 by sildenafil indi-
cated that the second messenger cGMP can blunt hyper-
trophic signals from pressure load and neurohormonal
stress perhaps by activation of a cardiac cGMP kinase I
(cGKI) pathway [2-4]. To test whether the predicted
hypertrophic phenotype of transgenic animals carrying a
genetic disruption of cGKI in the heart can be confirmed,
we analyzed the recently established cGKI rescue mice
(RM) [5]. We provide strong evidence that the cGKI pro-
tein is not present in cM of RM, whereas it is detectable in
the myocardium of control mice. We studied hypertrophy
in response to chronic β-adrenoreceptor stimulation by
isoproterenol (ISO) and identified significantly reduced
expression levels of the β1-adrenergic receptor in the
hearts of gene-targeted RM as compared to littermate con-
trols. However, the heart/body weight ratios (HW/BW)
and the mean cM cross-section area were increased to a
similar extent in both genotypes after the 7 days of ISO
(30 mg/kg/d). Up-regulation of fetal gene markers (NPPA,
Myh7,  PI-16) and down-regulation of genes which are
normally expressed in the adult heart (Myh6,  Serca2),
both indicative for pathological hypertrophy, were as well
not altered by the lack of cGKI in cM.
In summary, the presented data indicates that cGKI sign-
aling in cM does not protect the heart from the maladap-
tive hypertrophy program induced by chronic β-
adrenergic stimulation that activates Gs protein-coupled
receptor pathways.
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